证券代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------|------------------------------------------------------------------------------------|------------| | | | 编号： | 2021-001 | | 投 资 者关 系 活 | □ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | √ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他 （电话会议） | | | | 参 与 单位 名 称 及人员姓名 | 线上公众投资者 | | | | 时间 | 2021 年 5 月 11 日 | | | | 地点 | "奥美医疗投资者关系"微信小程序 | | | | 上 市 公司 接 待 | ...

证券代码：002950 证券简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | --- | |---------------|------------------------------------------------------|--------------------------------------------------|---------------| | | | | | | 投资者 关系活 | □ 特定对象调研 | □ 分析师会议 | | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | √ 其他 湖北上市公司 2021 | 年度投资者网上集体接待日活动 | | | 参与单 位名称 | 线上公众投资者 | | | | 及人员姓名 | | | | | 时间 | 2021 年 6 月 24 日 | | | | 地点 | 全景网投资者关系互动平台 | | | | 上市公 司接待 | 董事、副总裁兼董事会秘书 | 杜先举；证券事 ...

股票代码：002950 股票简称：奥美医疗 奥美医疗用品股份有限公司投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-------| | | | | | | 投资者关系活动类 | □ 特定对象调研 □ | 分析师会议 | | | 别 | □ 媒体采访 | √业绩说明会 | | | | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及人 | 线上参与公司奥美医疗 | 2021 年度网上业绩说明会的投 | | | 员姓名 | 资者 | | | | 时间 | 202 ...

Revenue and Profitability - The company's revenue for Q3 2022 was ¥932,733,147, representing a 12.29% increase year-over-year, and a total revenue of ¥3,067,161,380.95 for the year-to-date, which is a 31.79% increase compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2022 was a loss of ¥93,224,648.75, a decrease of 202.04% year-over-year, while the year-to-date net profit was ¥196,873,537.48, down 40.18% compared to the previous year[3] - Total operating revenue for the current period reached ¥3,067,161,380.95, a significant increase from ¥2,327,252,559.38 in the previous period, representing a growth of approximately 31.7%[16] - Net profit for the current period was ¥196,749,394.55, down from ¥330,867,284.85 in the previous period, reflecting a decrease of approximately 40.5%[17] - The total comprehensive income for the current period was ¥289,534,919.49, slightly down from ¥323,648,414.38 in the previous period, a decrease of about 10.5%[17] Cash Flow and Financial Position - The cash flow from operating activities for the year-to-date was ¥900,860,648.94, showing a significant increase of 275.58% compared to the same period last year[3] - The net cash flow from operating activities improved to ¥900,860,648.94, compared to ¥239,857,506.40 in the previous period, indicating a growth of about 274.5%[19] - The company reported a net cash outflow from investing activities of ¥1,067,174,157.15, compared to a net outflow of ¥941,221,354.73 in the previous period, indicating an increase in cash outflow of about 13.4%[19] - Net cash flow from financing activities was -236,928,160.88 CNY in Q3 2022, compared to -313,448,681.28 CNY in Q3 2021, indicating an improvement year-over-year[20] - The company reported a net decrease in cash and cash equivalents of -382,609,401.33 CNY for Q3 2022, compared to -1,013,433,841.51 CNY in Q3 2021, showing a significant reduction in cash burn[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,542,843,747.46, reflecting a 10.75% increase from the end of the previous year[3] - Total assets as of September 30, 2022, amounted to CNY 5,542,843,747.46, an increase from CNY 5,004,829,011.10 at the beginning of the year[13] - Total liabilities reached CNY 2,634,249,126.42, compared to CNY 2,252,783,574.08 at the beginning of the year[14] - The company's total equity attributable to shareholders at the end of the reporting period was ¥2,907,662,991.66, a 5.62% increase from the end of the previous year[3] - The company's total equity as of September 30, 2022, was CNY 2,908,594,621.04, up from CNY 2,752,045,437.02[14] Shareholder Information - The number of common shareholders at the end of the reporting period was 47,822[10] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[10] Expenses and Financial Performance - The company's basic and diluted earnings per share for Q3 2022 were both -¥0.1472, a decrease of 202.04% year-over-year[3] - The company's research and development expenses decreased by 21.46% year-over-year to ¥45,635,755.64[8] - The financial expenses increased significantly by 1636.59% year-over-year to ¥199,980,941.51, primarily due to exchange losses from the depreciation of the RMB against the USD[8] - The company experienced a loss in investment income of ¥9,128,577.84, contrasting with a gain of ¥23,145,832.72 in the previous period[16] - Basic earnings per share decreased to ¥0.3109 from ¥0.5197, reflecting a decline of approximately 40%[17]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 2.13 billion, representing a 42.62% increase compared to CNY 1.50 billion in the same period last year [29]. - The net profit attributable to shareholders for the first half of 2022 was approximately CNY 290.10 million, a 22.01% increase from CNY 237.77 million in the previous year [29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately CNY 307.22 million, reflecting a significant increase of 55.47% compared to CNY 197.61 million in the same period last year [29]. - The net cash flow from operating activities reached approximately CNY 559.15 million, a remarkable increase of 698.05% from CNY 70.06 million in the previous year [29]. - The total assets at the end of the reporting period were approximately CNY 5.66 billion, up 13.07% from CNY 5.00 billion at the end of the previous year [29]. - The net assets attributable to shareholders at the end of the reporting period were approximately CNY 2.95 billion, an increase of 7.12% from CNY 2.75 billion at the end of the previous year [29]. - The company reported a basic earnings per share of CNY 0.4581, which is a 22.00% increase compared to CNY 0.3755 in the same period last year [29]. - The weighted average return on equity for the reporting period was 10.01%, an increase of 2.46% from 7.55% in the previous year [29]. Market Strategy and Expansion - The company plans to enhance its market presence in emerging markets such as the Middle East and Africa, as well as expand its domestic medical supplies market share [6]. - The company aims to strengthen its partnerships with key international medical device brands to secure stable revenue streams [6]. - The company is focused on the medical dressing market, which is expected to grow due to increasing demands for wound healing and comfort from patients [38]. - The company is positioned to capitalize on the growing demand for high-quality medical dressings in both domestic and international markets [43]. - The company aims to expand its product line by adding high-value consumables based on existing products like Vaseline gauze [46]. - The company has developed a series of new products tailored to different market needs, including sterile care packages for medical institutions and a range of personal protective products for the retail market [69]. Risk Management - The company has implemented strategies to mitigate risks associated with raw material price fluctuations, including centralized procurement and local sourcing to manage costs effectively [8]. - The company is exposed to foreign exchange risks due to its foreign currency-denominated sales, and it has adopted measures such as careful currency selection and the use of financial instruments to hedge against these risks [9]. - The company has established a professional derivatives trading team to manage risks related to raw material procurement and currency fluctuations [11]. - The company emphasizes the importance of maintaining a robust internal control system for its derivative transactions to mitigate trading risks [11]. - The company has implemented a comprehensive risk management system for foreign exchange derivative transactions, ensuring no speculative operations are conducted [110]. Product Development and Innovation - The company is committed to ongoing research and development of new products and technologies to enhance its competitive edge in the medical supplies market [6]. - The company has developed a comprehensive range of wound care solutions, including non-stick wound pads and various types of gauze [47]. - The surgical consumables segment includes innovative products like X-ray detectable gauze and non-woven surgical drapes [50]. - The company has invested in R&D and innovation, resulting in multiple software copyrights and patents, maintaining its competitive edge in the medical dressing sector [77]. - The company aims to continue focusing on market demand and core technologies to create tailored product solutions for different scenarios [70]. Corporate Governance and Financial Management - The company will not distribute cash dividends or issue bonus shares, indicating a focus on reinvestment [12]. - The company has implemented a comprehensive quality management system, adhering to international standards such as ISO13485 and FDA regulations, which has strengthened customer confidence [76]. - The company has no significant changes in asset measurement attributes during the reporting period [93]. - The company has not reported any significant litigation or arbitration matters during the reporting period [132]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period [137]. Social Responsibility and Community Engagement - In response to the COVID-19 pandemic, the company donated over 2 million RMB worth of medical supplies to various regions, including 500,000 RMB worth of supplies to Shenzhen [120]. - The company supplied over 40 million masks and 100,000 bottles of hand sanitizer to Shanghai during the peak of the outbreak from March to April 2022 [123]. - The company donated nearly 4.78 million surgical masks valued at approximately 2 million RMB to support high school students and staff during the 2022 examination period [124]. - The company provided 200,000 KN95 masks and medical protective masks valued at 450,000 RMB to the Hong Kong Federation of Trade Unions to assist in combating COVID-19 [121]. - The company arranged for 17.5 containers of supplies to support Shanghai's epidemic prevention efforts [123]. Financial Position and Assets - The company's total assets increased to CNY 4,235,642,730.72, compared to CNY 4,147,088,396.72 at the end of the first half of 2021 [181]. - The company's total liabilities increased to RMB 2,709,319,506.74 as of June 30, 2022, up from RMB 2,252,783,574.08, indicating a rise of approximately 20.2% [177]. - The company's equity attributable to shareholders rose to RMB 2,948,899,521.84 from RMB 2,752,953,286.33, marking an increase of about 7.1% [177]. - The company's inventory stood at RMB 853,700,859.44 as of June 30, 2022, slightly up from RMB 846,628,943.74 at the beginning of the year [175]. - The company's accounts receivable rose to RMB 502,029,260.61 from RMB 425,145,128.23, an increase of about 18.1% [175].

奥美医疗用品股份有限公司 2022 年第一季度报告全文 证券代码：002950 证券简称：奥美医疗 公告编号：2022-017 奥美医疗用品股份有限公司 2022 年第一季度报告 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 □ 适用 √ 不适用 (二)非经常性损益项目和金额 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 √ 适用 □ 不适用 单位：元 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益项 目的情况说明 1 □ 适用 √ 不适用 奥美医疗用品股份有限 ...

Financial Performance - The company's operating revenue for 2021 was CNY 2,925,554,887.71, a decrease of 23.70% compared to CNY 3,834,498,022.40 in 2020 [28]. - The net profit attributable to shareholders for 2021 was CNY 431,214,849.37, down 62.75% from CNY 1,157,526,566.11 in the previous year [28]. - The net profit after deducting non-recurring gains and losses was CNY 343,185,202.57, a decline of 67.66% compared to CNY 1,061,118,748.22 in 2020 [28]. - The net cash flow from operating activities was CNY 374,852,202.76, a significant drop of 73.91% from CNY 1,436,740,713.51 in the previous year [28]. - Basic earnings per share decreased to CNY 0.68, down 62.84% from CNY 1.83 in 2020 [28]. - Total assets at the end of 2021 were CNY 5,004,829,011.10, an increase of 3.06% from CNY 4,856,080,464.92 at the end of 2020 [28]. - The net assets attributable to shareholders decreased to CNY 2,752,953,286.33, down 5.42% from CNY 2,910,700,528.82 at the end of 2020 [28]. - The company reported a weighted average return on equity of 15.65%, a decrease of 28.35% from 44.00% in 2020 [28]. - The company achieved total operating revenue of CNY 292,555.49 million, a decrease of 23.70% year-on-year, and a net profit attributable to shareholders of CNY 43,121.48 million, down 62.75% year-on-year [82]. - The company's overseas operating revenue was CNY 233,586.22 million, accounting for 79.84% of total revenue, while domestic revenue was CNY 58,969.27 million, representing 20.16% of total revenue, with a year-on-year decline of 50.92% [84]. - The proportion of pandemic-related revenue in total revenue decreased to 14.82% in 2021 from 39.92% in 2020, indicating a more balanced revenue structure [85]. Market Strategy and Expansion - The company is expanding into emerging markets in the Middle East, Asia, Africa, and Latin America to mitigate risks associated with concentrated overseas markets [7]. - The company is focused on increasing its market share in domestic medical supplies and infection protection markets [7]. - The company aims to leverage its unique manufacturing capabilities to expand its market presence and explore potential mergers and acquisitions for growth [53]. - The company is actively expanding its domestic market share through various channels, including e-commerce, OTC markets, and hospital partnerships, with products now available in over 70,000 pharmacies [88]. - The company is focused on building advanced production capacity and integrating automation and information technology into its manufacturing processes [93]. - The company plans to enhance supply chain management and expand product categories in response to domestic procurement policies and UDI regulations, leveraging its experience in overseas GPO participation [138]. Product Development and Innovation - The company is positioned as a leading player in the domestic medical dressing industry, focusing on product innovation and process upgrades [50]. - The company continues to expand its low-value consumables product line, providing a one-stop product supply service to meet various usage scenarios [53]. - The company is extending its product line into high-value consumables based on high-margin products like petroleum jelly gauze, creating a multi-tiered product offering [53]. - The company has launched a series of consumer products in the respiratory protection, wound care, and daily care categories, leveraging over 20 years of experience in textile and medical products [60]. - The company has developed various new products, including medical cold compresses and oral rinses, expanding its product portfolio [68]. - The company plans to develop high-end medical dressings, including silicone foam dressings and hydrocolloid dressings, to expand its market presence [111]. Risk Management - The company faces risks from high reliance on export revenue, which is influenced by international market conditions and currency fluctuations [7]. - The company emphasizes the importance of foreign exchange risk management and employs various financial tools to control potential risks [9]. - The company has established a professional team for derivative trading to ensure effective risk management and compliance with internal controls [11]. - The company utilizes derivative instruments like cotton futures and forward foreign exchange contracts to hedge against price volatility and currency risks [10]. - The company has established a risk management system for its foreign exchange derivative products, ensuring compliance with relevant laws and regulations [132]. Corporate Governance - The company has implemented a robust governance structure, complying with relevant laws and regulations to enhance transparency and investor relations [146]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring complete control over financial decisions [156]. - The company has a clear ownership of all assets, including production facilities, trademarks, and patents, with no asset occupation by controlling shareholders [156]. - The board of directors includes experienced professionals, with the chairman and president, Cui Jinhai, having held the position since September 2016 [162]. - The company has maintained a stable governance structure with independent directors and supervisors since its establishment [162]. Social Responsibility and Community Engagement - The company actively responded to the COVID-19 pandemic by establishing a special supply group to ensure the production and delivery of medical supplies, including N95 masks and protective clothing, to various regions in need [192]. - In 2021, the company donated over 3 million RMB worth of medical supplies to support flood relief efforts in Henan province following severe flooding [192]. - The company received recognition from the Hubei Charity Federation for its contributions to disaster relief efforts during the floods [195]. - The company was awarded the title of "Most Growth-Oriented Listed Company in the Health Industry" and "Most Socially Responsible Listed Company" in the 2021 China Listed Company Reputation Rankings [197]. - The company has a commitment to employee welfare, having been recognized as a "Harmonious Enterprise" by the Hubei Provincial Human Resources and Social Security Department [198]. Employee Management and Development - The total number of employees at the end of the reporting period was 4,964, including 3,871 at the parent company and 1,093 at major subsidiaries [175]. - The company has established a training system focused on strategic talent development to enhance overall employee quality and management capabilities [177]. - The professional composition included 3,881 production personnel, 52 sales personnel, 411 technical personnel, 34 financial personnel, and 586 administrative personnel [175]. - The company has a performance-based compensation policy that aligns with organizational and individual performance assessments [165]. - The company is committed to regularly reviewing its compensation and incentive systems to ensure competitiveness [165].

Financial Performance - The company's revenue for Q3 2021 was ¥830,658,090.81, a decrease of 0.31% compared to the same period last year, and a year-to-date revenue of ¥2,327,252,559.38, down 24.65% year-on-year [4]. - Net profit attributable to shareholders for Q3 2021 was ¥91,362,715.90, a decline of 63.09%, with a year-to-date net profit of ¥329,132,304.17, down 65.69% [4]. - The basic earnings per share for Q3 2021 was ¥0.1443, reflecting a decrease of 63.09% compared to the same period last year [4]. - Total operating revenue for the current period is $2,327,252,559.38, down from $3,088,744,908.97 in the previous period, representing a decrease of approximately 24.6% [20]. - Net profit for the current period is $330,867,284.85, a decline of 65.5% compared to $960,718,427.09 in the same period last year [21]. - Basic earnings per share decreased to $0.5197 from $1.5146, reflecting a drop of approximately 65.7% [22]. - The total comprehensive income for the current period is $323,648,414.38, down from $942,347,156.76 in the previous period, a decrease of about 65.6% [22]. Assets and Liabilities - The company's total assets at the end of Q3 2021 were ¥4,878,627,077.32, an increase of 0.46% from the end of the previous year [5]. - Current assets decreased to CNY 2,211,661,598.31 from CNY 2,836,267,822.98, representing a decline of approximately 22% [16]. - Total liabilities increased to CNY 2,209,997,979.88 from CNY 1,932,969,618.30, marking an increase of approximately 14% [18]. - Total equity decreased to CNY 2,668,629,097.44 from CNY 2,923,110,846.62, a decline of approximately 9% [18]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥239,857,506.40, down 79.31% compared to the same period last year [4]. - Cash flow from operating activities generated a net amount of $239,857,506.40, significantly lower than $1,159,186,199.55 in the previous period [25]. - In Q3 2021, the net cash flow from financing activities was -313,448,681.28 CNY, compared to a positive 328,114,054.69 CNY in the same period last year [26]. - Total cash and cash equivalents at the end of Q3 2021 were 288,406,450.62 CNY, down from 837,610,741.62 CNY at the end of Q3 2020 [26]. Investments and Expenses - Research and development expenses increased by 17.82% to ¥58,101,424.18, indicating a focus on innovation [10]. - The company reported a significant increase in long-term equity investments by 88.36% to ¥741,452,100.48, reflecting increased external investments [10]. - The company experienced a 77.85% decrease in cash and cash equivalents, totaling ¥288,406,450.62, primarily due to profit distribution and increased investments [10]. - Cash inflow from investment activities totaled $1,948,559,246.47, compared to $1,442,324,531.71 in the previous period, indicating an increase of about 35.2% [25]. - Cash outflow from investment activities increased to $2,889,780,601.20 from $2,328,805,064.68, representing a rise of approximately 24% [25]. Shareholder Information - The number of common shareholders at the end of the reporting period was 51,122 [13]. - The company received government subsidies amounting to ¥68,463,898.47, an increase of 77.56% compared to the previous year [10]. Other Information - The company did not undergo an audit for the Q3 2021 report [27]. - The new leasing standards were not applicable for the financial statements in 2021 [27].

Revenue and Financial Performance - The company reported significant revenue growth in its main business areas, including wound care and infection prevention, largely driven by increased overseas sales due to the pandemic [7]. - The company's operating revenue for the first half of 2021 was ¥1,496,594,468.57, a decrease of 33.65% compared to ¥2,255,525,258.33 in the same period last year [23]. - The net profit attributable to shareholders was ¥237,769,588.27, down 66.59% from ¥711,645,802.44 in the previous year [23]. - The net cash flow from operating activities was ¥70,064,884.14, reflecting a significant decline of 91.73% compared to ¥847,505,458.58 in the same period last year [23]. - The basic earnings per share decreased to ¥0.3755, down 66.59% from ¥1.1238 in the previous year [23]. - The company's total revenue for the current period is ¥1,496,594,468.57, representing a decrease of 33.65% compared to ¥2,255,525,258.33 in the same period last year [86]. - The company's pandemic-related revenue accounted for only 14.71% of total revenue in the first half of 2021, indicating strong risk resistance compared to industry peers [69]. - In the first half of 2021, the company achieved total revenue of CNY 1,496,594,468.57, a decrease of 33.65% year-on-year, while net profit attributable to shareholders was CNY 237,769,588.27, down 66.59% year-on-year [67]. Market Expansion and Strategy - The company plans to expand its market presence in emerging markets such as the Middle East and Africa, aiming to reduce reliance on concentrated overseas markets [3]. - The company aims to increase its market share in the domestic medical supplies sector to diversify its revenue sources [3]. - The company is focusing on expanding its market presence in the global medical dressing outsourcing sector, which has seen significant growth due to increased production outsourcing in developed countries [37]. - The company is expanding into emerging markets in the Middle East, Asia, Africa, and Latin America to mitigate risks associated with overseas market concentration [107]. Product Development and Innovation - The company is focused on optimizing its product line and accelerating the construction of its disease control and protection product manufacturing base [7]. - The company emphasizes the importance of product innovation and development in response to the growing demand for advanced wound healing solutions driven by an aging population [37]. - The company has developed a variety of new products, such as the OB pads designed for postpartum use, which feature high absorbency and hygiene protection [35]. - New product developments include high-efficiency medical masks that have already been launched in the market [81]. - The company is committed to providing high-quality products and services, with a focus on long-term demand and competitive pricing in the post-pandemic era [69]. Financial Management and Risk Control - The company has implemented a dual procurement strategy for raw materials, combining centralized purchasing for bulk commodities and localized sourcing to mitigate cost fluctuations [4]. - The company is actively enhancing its foreign exchange risk management practices, including the use of forward contracts and options to hedge against currency fluctuations [4]. - The company has established a robust internal control system for derivative trading to manage risks associated with commodity price volatility and foreign exchange rates [5]. - The company is implementing risk control measures for its derivative investments, focusing on hedging against currency and interest rate fluctuations [104]. - The company faces risks from high reliance on foreign sales, which are influenced by export policies, currency exchange rates, and international market fluctuations [107]. Research and Development - R&D expenses for the first half of 2021 amounted to ¥39,780,603.49, representing a 36.46% increase year-on-year [78]. - The company acquired a 55% stake in Wuhan Baima Biotechnology Co., enhancing its R&D capabilities in biopolymer materials [80]. - The company holds 196 patents as of August 20, 2021, an increase of 111 patents year-on-year, reflecting a 115.6% growth [79]. - The company has focused on R&D innovation, investing in automation and smart management systems, resulting in several software copyrights [60]. Environmental and Social Responsibility - The company has implemented a comprehensive wastewater treatment process, ensuring that discharge concentrations meet the required standards [122]. - The total discharge of COD is 88.468 tons per year, with a concentration of 203.9928 mg/L, which is compliant with the standards [122]. - The company actively responds to national environmental protection policies and conducts self-inspections [122]. - The company has passed multiple social responsibility audits during the reporting period [125]. Shareholder and Equity Information - The total number of shares before the change was 633,265,407, with a post-change total of 633,265,407, indicating no overall change in total shares [156]. - The largest shareholder, Cui Jinhai, holds 145,794,859 shares, representing 23.02% of total shares [160]. - The company has not reported any share repurchase or reduction activities during the reporting period [157]. - The total approved external guarantees during the reporting period amounted to CNY 337,435.05 million, with actual guarantees totaling CNY 60,428.8 million [149].

Financial Performance - The company's operating revenue for Q1 2021 was ¥820,581,799.40, representing a 37.32% increase compared to ¥597,558,015.66 in the same period last year[8] - The net profit attributable to shareholders for Q1 2021 was ¥116,304,971.88, up 27.53% from ¥91,195,258.97 in the previous year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,177,115.09, an increase of 11.45% compared to ¥88,093,169.40 in the same period last year[8] - The basic earnings per share for Q1 2021 were ¥0.1837, up 27.57% from ¥0.1440 in the same period last year[8] - The diluted earnings per share for Q1 2021 were also ¥0.1837, reflecting the same increase of 27.57% compared to ¥0.1440 in the previous year[8] - The company reported a net profit margin improvement, with net profit increasing due to higher revenues despite rising costs[40] Cash Flow - The net cash flow from operating activities for Q1 2021 was ¥13,427,440.70, a significant decrease of 96.18% from ¥351,379,371.51 in the previous year[8] - The cash flow from operating activities was CNY 624,769,899.08, down from CNY 810,309,454.99 in the previous year[48] - Operating cash inflow for Q1 2021 was CNY 737.77 million, a decrease from CNY 874.93 million in Q1 2020, resulting in a net cash flow from operating activities of CNY 13.43 million compared to CNY 351.38 million in the previous year[49] - The company's cash and cash equivalents decreased by CNY 259.49 million in Q1 2021, resulting in an ending balance of CNY 1,042.35 million compared to CNY 788.04 million at the end of Q1 2020[50] - The company reported a significant increase in cash received from other operating activities, amounting to CNY 912.32 million, compared to CNY 179.02 million in the previous year[52] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,299,173,298.76, reflecting a 9.12% increase from ¥4,856,080,464.92 at the end of the previous year[8] - The net assets attributable to shareholders at the end of the reporting period were ¥3,033,746,569.60, which is a 4.23% increase from ¥2,910,700,528.82 at the end of the previous year[8] - Total liabilities rose to CNY 2,252,623,591.18 from CNY 1,932,969,618.30, reflecting increased financial obligations[34] - The company's total assets as of March 31, 2021, amounted to CNY 4,116,504,849.34, an increase from CNY 3,787,115,816.84 at the end of 2020[36] Investments - The company made a long-term equity investment of CNY 543,487,043.10, a 38.07% increase, primarily in Sichuan Zhenghexiang Health Pharmacy Chain Co., Ltd.[15] - Long-term investments grew to CNY 1,437,340,027.95 from CNY 1,239,913,358.88, suggesting strategic investment in growth opportunities[36] Expenses - Research and development expenses surged by 218.02% to CNY 30,817,052.35, reflecting the company's commitment to enhancing R&D investment[16] - Financial expenses rose significantly by 400.32% to CNY 26,115,424.97, mainly due to increased foreign currency borrowings[15] - The gross profit margin was impacted by a 47.42% increase in operating costs, totaling CNY 566,067,253.13[15] - The company reported a 55.06% decrease in selling expenses, amounting to CNY 14,079,934.36, due to the reclassification of transportation costs under operating costs[15] Market and Risk Management - The company has engaged in trust financial products with an investment amount of CNY 40 million, with no overdue amounts reported[25] - The company has implemented measures to mitigate market risks, including foreign exchange derivatives to lock in exchange rates and reduce volatility risks[22] Other Information - The company reported non-recurring gains and losses totaling ¥18,127,856.79 for the reporting period[9] - The company reported no significant changes in accounting policies or estimates compared to the previous reporting period[24] - There were no violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[26] - The company has not undergone an audit for the Q1 2021 report, indicating that the figures presented are unaudited[55]